- Advertisement -

Find a job

Subscribe for free

All things Pharma

Adaptimmune transfer tumour killing T-cell program to GSK

GlaxoSmithKline plc and Adaptimmune Therapeutics plc , a leader in T-cell therapy to treat cancer, announced the transition of the development program for GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, to GSK.

As a result of the transition, GSK assumes full responsibility for future research, development, and potential commercialisation of this pioneering therapy, and Adaptimmune will receive £21.2 million from GSK.

“GSK ‘794 points to the  transformational nature of this T-cell therapy. This is the first therapy to show clinical response in solid tumours”

GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognising with high affinity the tumour-specific antigen, NY-ESO. When the modified cells are re-infused into the patient, they recognise and kill tumour cells that express the NY-ESO antigen. NY-ESO is expressed at various levels across different tumours, and appears to be expressed at high levels in defined sub-types of soft tissue sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer (NSCLC), ovarian cancer and gastro-intestinal cancers.

Effective immediately, GSK will assume responsibilities for all ongoing studies of NY-ESO SPEAR T‑cells, including those in NSCLC, and the combination study with KEYTRUDA® in multiple myeloma. Successful continuation of development and subsequent commercialisation of GSK ‘794 will trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales.

Dr. Hal Barron, President R&D, GSK said, “The data we’ve seen for GSK ‘794 point to the potentially transformational nature of this T-cell therapy, as this is the first cell therapy to show clinical response in solid tumours. The concept of cells as medicines is an exciting component of our immuno-oncology portfolio and leverages our expertise in manufacturing T-cell therapies.”

James Noble, Chief Executive Officer at Adaptimmune, said “We are extremely proud of the partnership with GSK and the pioneering work we have led over the years with NY-ESO SPEAR T-cells, as the foundation of our targeted TCR therapies, showing responses in two solid tumours and treating more than 80 patients in six different indications. We will continue the preclinical work with GSK on its next target, PRAME.”

- Advertisement -
Hannah Alderton
Hannah is an Account Executive at E4H.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription